- Home
- IHS vs IRON Comparison
IHS vs IRON Comparison
Compare IHS & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHS
- IRON
- Stock Information
- Founded
- IHS 2001
- IRON 2017
- Country
- IHS United Kingdom
- IRON United States
- Employees
- IHS N/A
- IRON N/A
- Industry
- IHS Telecommunications Equipment
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- IHS Telecommunications
- IRON Health Care
- Exchange
- IHS Nasdaq
- IRON Nasdaq
- Market Cap
- IHS 1.6B
- IRON 1.4B
- IPO Year
- IHS 2021
- IRON N/A
- Fundamental
- Price
- IHS $5.70
- IRON $44.24
- Analyst Decision
- IHS Strong Buy
- IRON Strong Buy
- Analyst Count
- IHS 5
- IRON 10
- Target Price
- IHS $7.60
- IRON $83.80
- AVG Volume (30 Days)
- IHS 883.8K
- IRON 397.9K
- Earning Date
- IHS 05-16-2025
- IRON 05-07-2025
- Dividend Yield
- IHS N/A
- IRON N/A
- EPS Growth
- IHS N/A
- IRON N/A
- EPS
- IHS N/A
- IRON N/A
- Revenue
- IHS $1,711,225,000.00
- IRON N/A
- Revenue This Year
- IHS $0.51
- IRON N/A
- Revenue Next Year
- IHS $6.34
- IRON N/A
- P/E Ratio
- IHS N/A
- IRON N/A
- Revenue Growth
- IHS N/A
- IRON N/A
- 52 Week Low
- IHS $2.44
- IRON $28.25
- 52 Week High
- IHS $5.75
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- IHS 67.44
- IRON 45.99
- Support Level
- IHS $4.85
- IRON $40.36
- Resistance Level
- IHS $6.00
- IRON $47.21
- Average True Range (ATR)
- IHS 0.25
- IRON 2.87
- MACD
- IHS 0.08
- IRON 0.10
- Stochastic Oscillator
- IHS 77.36
- IRON 37.67
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.